Literature DB >> 21676681

Long-term results after Carpentier-Edwards pericardial aortic valve implantation, with attention to the impact of age.

Karl F Welke1, Yingxing Wu, Gary L Grunkemeier, Aftab Ahmad, Albert Starr.   

Abstract

BACKGROUND: The purpose of this study was to determine long-term patient survival and valve durability for Carpentier-Edwards pericardial valves (Edwards Lifesciences) implanted in the aortic position, with specific attention to the impact of patient age.
METHODS: We performed a retrospective cohort study of 2168 patients who underwent implantation of a Carpentier-Edwards pericardial aortic valve between 1991 and 2008. The mean follow-up time was 4.5 years. Primary outcomes of interest were mortality and valve explantation. Survival curves and event-free curves were obtained with the Kaplan-Meier method and compared with the log-rank test.
RESULTS: Survival was 92% at 1 year, 73% at 5 years, 38% at 10 years, and 18% at 15 years. Although the mortality rate of younger patients was worse than in the general population, older patients had significantly better survival than their contemporaries. Age was the independent variable most significantly associated with explantation. There was an early hazard phase for patients between 21 and 49 years of age, such that the freedom from explantation was 89% at 3 years. By 10 years, the freedom from explantation was 58% for patients 21 to 49 years of age, compared with 68% for patients 50 to 64 years, 93% for patients 65 to 74 years, and 99% for patients 75 years of age and older.
CONCLUSION: We found good long-term survival and durability. Older patients had excellent freedom from explantation, whereas younger patients fared worse. As our population ages, this information becomes increasingly important. Assessing the durability of this pericardial aortic valve may aid in predicting the durability of the transcatheter aortic valves that share the same leaflets.

Entities:  

Mesh:

Year:  2011        PMID: 21676681     DOI: 10.1532/HSF98.20101140

Source DB:  PubMed          Journal:  Heart Surg Forum        ISSN: 1098-3511            Impact factor:   0.676


  5 in total

1.  Noninferiority of Shanghai Cingular biotech's bovine pericardial valve preclinical study in juvenile ovine model.

Authors:  Jin-Miao Chen; Yu Ding; Shu-Yang Lu; Sun Pan; Mieradilijiang Abudupataer; Tao Hong; Chun-Sheng Wang
Journal:  J Thorac Dis       Date:  2016-06       Impact factor: 2.895

Review 2.  Current progress in tissue engineering of heart valves: multiscale problems, multiscale solutions.

Authors:  Daniel Y Cheung; Bin Duan; Jonathan T Butcher
Journal:  Expert Opin Biol Ther       Date:  2015-06-01       Impact factor: 4.388

Review 3.  Mechano-regulated cell-cell signaling in the context of cardiovascular tissue engineering.

Authors:  Cansu Karakaya; Jordy G M van Asten; Tommaso Ristori; Cecilia M Sahlgren; Sandra Loerakker
Journal:  Biomech Model Mechanobiol       Date:  2021-10-06

4.  Surgery for Young Adults With Aortic Valve Disease not Amenable to Repair.

Authors:  Mustafa Zakkar; Vito Domanico Bruno; Alexandru Ciprian Visan; Stephanie Curtis; Gianni Angelini; Emmanuel Lansac; Serban Stoica
Journal:  Front Surg       Date:  2018-03-02

5.  Stentless aortic valve replacement in the young patient: long-term results.

Authors:  Torsten Christ; Herko Grubitzsch; Benjamin Claus; Wolfgang Konertz
Journal:  J Cardiothorac Surg       Date:  2013-04-08       Impact factor: 1.637

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.